Pharmaceutical combinations of beta-3 adrenergic receptor agonists and muscarinic receptor antagonists
Pharmaceutical combinations comprising a beta-3 adrenergic receptor agonist and a muscarinic receptor antagonist, and methods for their use are disclosed. Disclosed combinations include solabegron and oxybutynin. Methods of using the pharmaceutical combinations for the treatment of one or more symptoms associated with overactive bladder, for example, frequency of urgency, nocturia, and urinary incontinence, are also disclosed.
1. A combination comprising:
(i) a therapeutically effective amount of a beta-3 adrenergic receptor agonist selected from the group consisting of solabegron and pharmaceutically acceptable salts thereof; and
(ii) a therapeutically effective amount, or a sub-therapeutically effective amount, of a muscarinic receptor antagonist selected from the group consisting of tolterodine, oxybutynin, trospium, solifenacin, darifenacin, propiverine, fesoterodine, and pharmaceutically acceptable salts thereof,
said combination being useful for relieving one or more symptoms of overactive bladder in a synergistic manner, versus the individual components (i) and (ii), wherein said one or more symptoms of overactive bladder are selected from the group consisting of frequency of urgency, nocturia, increase in urinary micturition frequency, and urinary incontinence.
2. The combination of claim 1 , wherein said muscarinic receptor antagonist is a compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of tolterodine, oxybutynin, and solifenacin.
3. The combination of claim 2 , comprising a therapeutically effective amount of said muscarinic receptor antagonist.
4. The combination of claim 1 , wherein said muscarinic receptor antagonist is a compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of tolterodine and oxybutynin.
5. The combination of claim 4 , comprising a therapeutically effective amount of said muscarinic receptor antagonist.
6. The combination of claim 1 , wherein said muscarinic receptor antagonist is oxybutynin, or a pharmaceutically acceptable salt thereof.
7. The combination of claim 1 , comprising a subtherapeutic effective amount of said muscarinic receptor antagonist.
8. A pharmaceutical composition comprising the combination of claim 1 , further comprising one or more pharmaceutically acceptable carriers, diluents, or excipients.
9. A combination comprising:
(i) a therapeutically effective amount of a compound of Formula (I),
or a pharmaceutically acceptable salt thereof; and
(ii) a therapeutically effective amount, or a sub-therapeutically effective amount, of a compound of Formula (II),
or a pharmaceutically acceptable salt thereof;
said combination being useful for relieving one or more symptoms of overactive bladder in a synergistic manner versus the individual components (i) and (ii), wherein said one or more symptoms of overactive bladder are selected from the group consisting of frequency of urgency, nocturia, increase in urinary micturition frequency and urinary incontinence.
10. The combination according to claim 9 , wherein the salt of the compound of Formula (I) is the hydrochloride salt.
11. A method of treating one or more symptoms of overactive bladder in a mammal, comprising administering to said mammal a combination comprising:
(i) a therapeutically effective amount of a beta-3 adrenergic receptor agonist selected from the group consisting of solabegron and pharmaceutically acceptable salts thereof; and
(ii) a therapeutically effective amount, or a sub-therapeutically effective amount, of a muscarinic receptor antagonist selected from the group consisting of tolterodine, oxybutynin, trospium, solifenacin, darifenacin, propiverine, fesoterodine, and pharmaceutically acceptable salts thereof;
said combination being useful for relieving one or more symptoms of overactive bladder in a synergistic manner versus the individual components (i) and (ii), wherein said one or more symptoms of overactive bladder are selected from the group consisting of frequency of urgency, nocturia, increase in urinary micturition frequency and urinary incontinence.
12. The method of claim 11 , wherein components (i) and (ii) are co-administered.
13. The method of claim 12 , wherein components (i) and (ii) are contained in a single dosage form.
14. The method of claim 11 , wherein components (i) and (ii) are administered separately.
15. The method of claim 14 , wherein there is a time delay between the administration of components (i) and (ii).
16. A method of treating one or more symptoms of overactive bladder in a mammal, comprising the step of administering to a mammal in need thereof, a therapeutically effective amount of the combination of claim 8 , wherein said one or more symptoms of overactive bladder are selected from the group consisting of frequency of urgency, nocturia, increase in urinary micturition frequency, and urinary incontinence.
17. A method of treating one or more symptoms of overactive bladder in a mammal, comprising administering to said mammal a combination comprising:
(i) a therapeutically effective amount of a compound of Formula (I),
or a pharmaceutically acceptable salt thereof; and
(ii) a therapeutically effective amount, or a sub-therapeutically effective amount, of a compound of Formula (II),
or a pharmaceutically acceptable salt thereof;
said combination being useful for relieving one or more symptoms of overactive bladder in a synergistic manner versus the individual components (i) and (ii), wherein said one or more symptoms of overactive bladder are selected from the group consisting of frequency of urgency, nocturia, increase in urinary micturition frequency, and urinary incontinence.
18. The method of claim 17 , wherein components (i) and (ii) are co-administered.
19. The method of claim 18 , wherein components (i) and (ii) are contained in a single dosage form.
20. The method of claim 17 , wherein components (i) and (ii) are administered separately.
21. The method of claim 20 , wherein there is a time delay between the administration of components (i) and (ii).
22. The method of claim 17 , wherein component (i) further comprises the compound of Formula (III)